Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.

导出 OA

翻译打印收藏纠错

作者： Jennifer R,Eads ^[1] ; Smitha S,Krishnamurthi ^[1] ; Joel,Saltzman ^[1] ; Joseph A,Bokar ^[1] ; Panos,Savvides ^[2] ; Neal J,Meropol ^[3] ; Joseph,Gibbons ^[4] ; Henry,Koon ^[1] ; Neelesh,Sharma ^[1] ; Lisa,Rogers ^[5] ; John J,Pink ^[1] ; Yan,Xu ^[3] ; Jan H,Beumer ^[6] ; John,Riendeau ^[7] ; Pingfu,Fu ^[1] ; Stanton L,Gerson ^[3] ; Afshin,Dowlati ^[1]

作者单位： Case Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA. ^[1] St. Joseph's Hospital and Medical Center, University of Arizona Comprehensive Cancer Center, University of Arizona, Phoenix, AZ, USA. ^[2] Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA. ^[3] Flatiron Health, New York, NY, USA. ^[4] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. ^[5] Case Comprehensive Cancer Center, Cleveland State University, Cleveland, OH, USA. ^[6] UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. ^[7] Case Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA. Afshin.dowlati@case.edu. ^[8]

关键词 DNA repair Methoxyamine Phase I TRC-102 Temozolomide